Literature DB >> 13911525

Antitumor activity of triazenoimidazoles.

Y F SHEALY, J A MONTGOMERY, W R LASTER.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS

Mesh：

Substances：

Year:  1962        PMID： 13911525     DOI： 10.1016/0006-2952(62)90130-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  7 in total

1.  [Carcinogenic activity of 13 aryldialkyl triazenes in BD-rats (author's transl)].

Authors:  R Preussmann; S Ivankovic; C Landschütz; J Gimmy; E Flohr; U Griesbach
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1974

Review 2.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Broad-spectrum antimicrobial activity of a new triazenoimidazole.

Authors:  R F Pittillo; D E Hunt
Journal:  Appl Microbiol       Date:  1967-05

4.  Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug.

Authors:  E Bonmassar; A Bonmassar; S Vadlamudi; A Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  1970-08       Impact factor: 11.205

5.  A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.

Authors:  D R Adkins; R Irvin; J Kuhn; D H Boldt; G D Roodman; D Salzman; C Freytes; D D Von Hoff; C F LeMaistre
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

6.  Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.

Authors:  B J Foster; D R Newell; J Carmichael; A L Harris; L A Gumbrell; M Jones; P M Goodard; A H Calvert
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

7.  A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.

Authors:  N M Bleehen; A H Calvert; S M Lee; P Harper; S B Kaye; I Judson; M Brampton
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.